- Home
- BMEA vs NEOV Comparison
BMEA vs NEOV Comparison
Compare BMEA & NEOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- NEOV
- Stock Information
- Founded
- BMEA 2017
- NEOV 2018
- Country
- BMEA United States
- NEOV United States
- Employees
- BMEA N/A
- NEOV N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- NEOV Industrial Machinery/Components
- Sector
- BMEA Health Care
- NEOV Miscellaneous
- Exchange
- BMEA Nasdaq
- NEOV Nasdaq
- Market Cap
- BMEA 65.8M
- NEOV 72.2M
- IPO Year
- BMEA 2021
- NEOV N/A
- Fundamental
- Price
- BMEA $1.73
- NEOV $3.44
- Analyst Decision
- BMEA Strong Buy
- NEOV Strong Buy
- Analyst Count
- BMEA 11
- NEOV 1
- Target Price
- BMEA $27.60
- NEOV $7.50
- AVG Volume (30 Days)
- BMEA 713.5K
- NEOV 231.5K
- Earning Date
- BMEA 05-05-2025
- NEOV 05-16-2025
- Dividend Yield
- BMEA N/A
- NEOV N/A
- EPS Growth
- BMEA N/A
- NEOV N/A
- EPS
- BMEA N/A
- NEOV N/A
- Revenue
- BMEA N/A
- NEOV $2,524,931.00
- Revenue This Year
- BMEA N/A
- NEOV $85.10
- Revenue Next Year
- BMEA N/A
- NEOV $281.25
- P/E Ratio
- BMEA N/A
- NEOV N/A
- Revenue Growth
- BMEA N/A
- NEOV N/A
- 52 Week Low
- BMEA $1.53
- NEOV $1.80
- 52 Week High
- BMEA $13.43
- NEOV $6.11
- Technical
- Relative Strength Index (RSI)
- BMEA 41.85
- NEOV 65.71
- Support Level
- BMEA $1.61
- NEOV $3.09
- Resistance Level
- BMEA $2.30
- NEOV $3.74
- Average True Range (ATR)
- BMEA 0.20
- NEOV 0.37
- MACD
- BMEA -0.00
- NEOV 0.09
- Stochastic Oscillator
- BMEA 21.74
- NEOV 80.33
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.